JP6660060B2 - ヒストンデメチラーゼ阻害剤 - Google Patents
ヒストンデメチラーゼ阻害剤 Download PDFInfo
- Publication number
- JP6660060B2 JP6660060B2 JP2017514411A JP2017514411A JP6660060B2 JP 6660060 B2 JP6660060 B2 JP 6660060B2 JP 2017514411 A JP2017514411 A JP 2017514411A JP 2017514411 A JP2017514411 A JP 2017514411A JP 6660060 B2 JP6660060 B2 JP 6660060B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010074870 Histone Demethylases Proteins 0.000 title claims description 18
- 102000008157 Histone Demethylases Human genes 0.000 title claims description 18
- 229940122680 Demethylase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 287
- 150000003839 salts Chemical class 0.000 claims description 167
- -1 fluoro compound Chemical class 0.000 claims description 150
- 125000003118 aryl group Chemical group 0.000 claims description 111
- 125000000217 alkyl group Chemical group 0.000 claims description 92
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 73
- 125000000623 heterocyclic group Chemical group 0.000 claims description 73
- 125000002947 alkylene group Chemical group 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 59
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 58
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 56
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 55
- 125000001072 heteroaryl group Chemical group 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 53
- 229910052736 halogen Inorganic materials 0.000 claims description 52
- 150000002367 halogens Chemical class 0.000 claims description 52
- 239000001257 hydrogen Substances 0.000 claims description 51
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 39
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 39
- 150000002431 hydrogen Chemical class 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 125000003282 alkyl amino group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 description 89
- 238000000034 method Methods 0.000 description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 70
- 238000006243 chemical reaction Methods 0.000 description 55
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 51
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 125000004432 carbon atom Chemical group C* 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 150000003254 radicals Chemical class 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 239000000126 substance Substances 0.000 description 21
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 18
- 108010033040 Histones Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 238000003016 alphascreen Methods 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 238000003818 flash chromatography Methods 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- REQFDBXEACLQPU-UHFFFAOYSA-N 2-(1h-imidazol-5-yl)pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC(C=2N=CNC=2)=C1 REQFDBXEACLQPU-UHFFFAOYSA-N 0.000 description 13
- 101000614013 Homo sapiens Lysine-specific demethylase 2B Proteins 0.000 description 13
- 102100040584 Lysine-specific demethylase 2B Human genes 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 125000003709 fluoroalkyl group Chemical group 0.000 description 13
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 12
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- NZHDJNMKYDTLEC-UHFFFAOYSA-N 2-(1h-imidazol-5-yl)pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(C=2N=CNC=2)=C1 NZHDJNMKYDTLEC-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 125000004450 alkenylene group Chemical group 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 9
- 239000007995 HEPES buffer Substances 0.000 description 9
- 102000006947 Histones Human genes 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000011987 methylation Effects 0.000 description 9
- 238000007069 methylation reaction Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 7
- 102100035864 Histone lysine demethylase PHF8 Human genes 0.000 description 7
- 101001000378 Homo sapiens Histone lysine demethylase PHF8 Proteins 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000003107 substituted aryl group Chemical group 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- SQHSJJGGWYIFCD-UHFFFAOYSA-N (e)-1-diazonio-1-dimethoxyphosphorylprop-1-en-2-olate Chemical compound COP(=O)(OC)C(\[N+]#N)=C(\C)[O-] SQHSJJGGWYIFCD-UHFFFAOYSA-N 0.000 description 4
- QRXBTPFMCTXCRD-UHFFFAOYSA-N 2-chloropyridine-4-carbonitrile Chemical compound ClC1=CC(C#N)=CC=N1 QRXBTPFMCTXCRD-UHFFFAOYSA-N 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010066805 F-Box Proteins Proteins 0.000 description 4
- 102000018700 F-Box Proteins Human genes 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000016624 JmjC domains Human genes 0.000 description 4
- 108050006228 JmjC domains Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 150000005840 aryl radicals Chemical class 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000003483 chromatin Anatomy 0.000 description 4
- 238000010520 demethylation reaction Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000000464 thioxo group Chemical group S=* 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- IAKGGJYLHBHSQD-UHFFFAOYSA-N 1-(azidomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CN=[N+]=[N-])C=C1 IAKGGJYLHBHSQD-UHFFFAOYSA-N 0.000 description 3
- QYVAZVXBSKNYFQ-UHFFFAOYSA-N 2-(1-methylimidazol-4-yl)pyridine-4-carbonitrile Chemical compound CN1C=NC(C=2N=CC=C(C=2)C#N)=C1 QYVAZVXBSKNYFQ-UHFFFAOYSA-N 0.000 description 3
- ZCJVFVODASCOHD-UHFFFAOYSA-N 2-(5-bromo-1-methylimidazol-4-yl)pyridine-4-carbonitrile Chemical compound CN1C=NC(C=2N=CC=C(C=2)C#N)=C1Br ZCJVFVODASCOHD-UHFFFAOYSA-N 0.000 description 3
- VCHJPYNNEGWXGJ-UHFFFAOYSA-N 2-[1-[(2-chlorophenyl)methyl]imidazol-4-yl]pyridine-4-carbonitrile Chemical compound ClC1=CC=CC=C1CN1C=C(C=2N=CC=C(C=2)C#N)N=C1 VCHJPYNNEGWXGJ-UHFFFAOYSA-N 0.000 description 3
- SNYJBMWRYMYBGB-UHFFFAOYSA-N 2-[5-[2-(cyclopropylmethoxy)-4-fluorophenyl]-1-methylimidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound Cn1cnc(c1-c1ccc(F)cc1OCC1CC1)-c1cc(ccn1)C1CNNN1 SNYJBMWRYMYBGB-UHFFFAOYSA-N 0.000 description 3
- MMOOBDAKJRQPGR-UHFFFAOYSA-N 4-[5-iodo-1-[(4-methoxyphenyl)methyl]triazol-4-yl]-2-[1-(2-naphthalen-1-ylethyl)imidazol-4-yl]pyridine Chemical compound COC1=CC=C(CN2N=NC(=C2I)C2=CC(=NC=C2)C2=CN(CCC3=CC=CC4=CC=CC=C34)C=N2)C=C1 MMOOBDAKJRQPGR-UHFFFAOYSA-N 0.000 description 3
- FFFOWUNIDRZMGR-UHFFFAOYSA-N C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)C=O Chemical compound C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)C=O FFFOWUNIDRZMGR-UHFFFAOYSA-N 0.000 description 3
- 0 CC*c1c(CC[n]2cnc(-c3nccc(C#N)c3)c2)cccc1 Chemical compound CC*c1c(CC[n]2cnc(-c3nccc(C#N)c3)c2)cccc1 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229910020366 ClO 4 Inorganic materials 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 101000613958 Homo sapiens Lysine-specific demethylase 2A Proteins 0.000 description 3
- 229910010082 LiAlH Inorganic materials 0.000 description 3
- 102100040598 Lysine-specific demethylase 2A Human genes 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 description 3
- 238000003633 gene expression assay Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 3
- 239000011755 sodium-L-ascorbate Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- WCEWCRAPSCLFOV-UHFFFAOYSA-N tributyl-(1-methylimidazol-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN(C)C=N1 WCEWCRAPSCLFOV-UHFFFAOYSA-N 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- ABFCOJLLBHXNOU-UHFFFAOYSA-N 2-(2-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=CC=C1O ABFCOJLLBHXNOU-UHFFFAOYSA-N 0.000 description 2
- KAMXYCVETYXNSB-UHFFFAOYSA-N 2-(2-phenylmethoxyphenyl)ethanol Chemical compound OCCC1=CC=CC=C1OCC1=CC=CC=C1 KAMXYCVETYXNSB-UHFFFAOYSA-N 0.000 description 2
- VUESODQWCISEQS-UHFFFAOYSA-N 2-(benzenesulfonyl)-3-[2-[1-[(2-chlorophenyl)methyl]imidazol-4-yl]pyridin-4-yl]prop-2-enenitrile Chemical compound C1(=CC=CC=C1)S(=O)(=O)C(C#N)=CC1=CC(=NC=C1)C=1N=CN(C=1)CC1=C(C=CC=C1)Cl VUESODQWCISEQS-UHFFFAOYSA-N 0.000 description 2
- ZFCFFNGBCVAUDE-UHFFFAOYSA-N 2-(benzenesulfonyl)acetonitrile Chemical compound N#CCS(=O)(=O)C1=CC=CC=C1 ZFCFFNGBCVAUDE-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JTTHRMNJZDYLDR-UHFFFAOYSA-N 2-[(6-chlorotriazolo[4,5-c]pyridin-1-yl)methoxy]ethyl-trimethylsilane Chemical compound ClC1=CC2=C(C=N1)N=NN2COCC[Si](C)(C)C JTTHRMNJZDYLDR-UHFFFAOYSA-N 0.000 description 2
- DTPABGHPXSLKIZ-UHFFFAOYSA-N 2-[1-[(2-chlorophenyl)methyl]imidazol-4-yl]pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(C=2N=CN(CC=3C(=CC=CC=3)Cl)C=2)=C1 DTPABGHPXSLKIZ-UHFFFAOYSA-N 0.000 description 2
- CDCAKPHONNAIQI-UHFFFAOYSA-N 2-[5-[2-(cyclopropylmethoxy)-4-fluorophenyl]-1-methylimidazol-4-yl]pyridine-4-carboxylic acid Chemical compound CN1C=NC(C=2N=CC=C(C=2)C(O)=O)=C1C1=CC=C(F)C=C1OCC1CC1 CDCAKPHONNAIQI-UHFFFAOYSA-N 0.000 description 2
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- JSIIDEVMRSVGKA-UHFFFAOYSA-N 6-chloro-2h-triazolo[4,5-c]pyridine Chemical compound C1=NC(Cl)=CC2=NNN=C21 JSIIDEVMRSVGKA-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- FPBTXNFPADZBHX-UHFFFAOYSA-N C(#C)C1=CC(=NC=C1)C=1N=CN(C=1)CCC1=CC=CC2=CC=CC=C12 Chemical compound C(#C)C1=CC(=NC=C1)C=1N=CN(C=1)CCC1=CC=CC2=CC=CC=C12 FPBTXNFPADZBHX-UHFFFAOYSA-N 0.000 description 2
- JKQLIDDJQPWZHO-UHFFFAOYSA-N C1(CC1)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound C1(CC1)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 JKQLIDDJQPWZHO-UHFFFAOYSA-N 0.000 description 2
- DBBMFKSEKWVNMI-UHFFFAOYSA-N C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)C#C Chemical compound C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)C#C DBBMFKSEKWVNMI-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- JDIHOESZMFASPH-UHFFFAOYSA-N ClC1=C(C=CC=C1)CN1C=NC(=C1)C1=NC=CC(=C1)C(=O)O Chemical compound ClC1=C(C=CC=C1)CN1C=NC(=C1)C1=NC=CC(=C1)C(=O)O JDIHOESZMFASPH-UHFFFAOYSA-N 0.000 description 2
- GPGBPBPIEKUSPD-UHFFFAOYSA-N ClC1=C(C=CC=C1)CN1C=NC(=C1)C1=NC=CC(=C1)CO Chemical compound ClC1=C(C=CC=C1)CN1C=NC(=C1)C1=NC=CC(=C1)CO GPGBPBPIEKUSPD-UHFFFAOYSA-N 0.000 description 2
- ZSBPPHUCNDMKKN-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)CN1C=NC(=C1)C1=NC=CC(=C1)C#C Chemical compound ClC1=C(C=CC=C1Cl)CN1C=NC(=C1)C1=NC=CC(=C1)C#C ZSBPPHUCNDMKKN-UHFFFAOYSA-N 0.000 description 2
- ITNUCWVKNADJQH-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)CN1C=NC(=C1)C1=NC=CC(=C1)C=O Chemical compound ClC1=C(C=CC=C1Cl)CN1C=NC(=C1)C1=NC=CC(=C1)C=O ITNUCWVKNADJQH-UHFFFAOYSA-N 0.000 description 2
- KWQJVSOSBMFHEW-UHFFFAOYSA-N ClC1=C(CN2C=NC(=C2)C2=NC=CC(C=O)=C2)C=CC=C1 Chemical compound ClC1=C(CN2C=NC(=C2)C2=NC=CC(C=O)=C2)C=CC=C1 KWQJVSOSBMFHEW-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241000239366 Euphausiacea Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical group O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 2
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 101150076630 jhdm-1 gene Proteins 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000019639 protein methylation Effects 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 150000003852 triazoles Chemical group 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- JIEDCOXRJDCFLW-UHFFFAOYSA-N trimethyl-[5-[2-(1-methylimidazol-4-yl)pyridin-4-yl]-2H-triazol-4-yl]silane Chemical compound C[Si](C1=C(N=NN1)C1=CC(=NC=C1)C=1N=CN(C=1)C)(C)C JIEDCOXRJDCFLW-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- KLLYGDXCCNXESW-UHFFFAOYSA-N (2-fluoroacetyl) 2-fluoroacetate Chemical compound FCC(=O)OC(=O)CF KLLYGDXCCNXESW-UHFFFAOYSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- AECBVDLERUETKG-UHFFFAOYSA-N 1-(2-bromoethyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1CCBr AECBVDLERUETKG-UHFFFAOYSA-N 0.000 description 1
- KMPOQRWMMPQZII-UHFFFAOYSA-N 1-(2-trimethylsilylethoxymethyl)triazolo[4,5-c]pyridine-6-carbaldehyde Chemical compound C[Si](CCOCN1N=NC=2C=NC(=CC=21)C=O)(C)C KMPOQRWMMPQZII-UHFFFAOYSA-N 0.000 description 1
- PURSZYWBIQIANP-UHFFFAOYSA-N 1-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1CBr PURSZYWBIQIANP-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- TZTXTIBZSSSFDI-UHFFFAOYSA-N 1-pyridin-2-ylpropan-2-one Chemical compound CC(=O)CC1=CC=CC=N1 TZTXTIBZSSSFDI-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- AHHQCRZKQHDXIY-UHFFFAOYSA-N 2-(1h-imidazol-5-yl)pyridine Chemical group N1C=NC=C1C1=CC=CC=N1 AHHQCRZKQHDXIY-UHFFFAOYSA-N 0.000 description 1
- VFBCORWVYBSEKH-UHFFFAOYSA-N 2-(2-phenoxyphenyl)ethanol Chemical compound OCCC1=CC=CC=C1OC1=CC=CC=C1 VFBCORWVYBSEKH-UHFFFAOYSA-N 0.000 description 1
- HCFLVIHAJMIHOD-UHFFFAOYSA-N 2-(benzenesulfonyl)-3-[2-[5-[2-(cyclopropylmethoxy)-4-fluorophenyl]-1-methylimidazol-4-yl]pyridin-4-yl]prop-2-enenitrile Chemical compound C1(=CC=CC=C1)S(=O)(=O)C(C#N)=CC1=CC(=NC=C1)C=1N=CN(C=1C1=C(C=C(C=C1)F)OCC1CC1)C HCFLVIHAJMIHOD-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- AZWPWSGCZRJBSF-UHFFFAOYSA-N 2-[1-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound C(C1CCCc2ccccc12)n1cnc(c1)-c1cc(ccn1)C1CNNN1 AZWPWSGCZRJBSF-UHFFFAOYSA-N 0.000 description 1
- IVVJKBCVIMNXCG-UHFFFAOYSA-N 2-[1-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)imidazol-4-yl]pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC(C=2N=CN(CC3C4=CC=CC=C4CCC3)C=2)=C1 IVVJKBCVIMNXCG-UHFFFAOYSA-N 0.000 description 1
- BEWMFPKEAHZTJV-UHFFFAOYSA-N 2-[1-(1-phenylethyl)imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound CC(c1ccccc1)n1cnc(c1)-c1cc(ccn1)C1CNNN1 BEWMFPKEAHZTJV-UHFFFAOYSA-N 0.000 description 1
- OATWMPVCUZPBCH-UHFFFAOYSA-N 2-[1-(1-phenylpropan-2-yl)imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound CC(Cc1ccccc1)n1cnc(c1)-c1cc(ccn1)C1CNNN1 OATWMPVCUZPBCH-UHFFFAOYSA-N 0.000 description 1
- VCSRTLBBVLAXOM-UHFFFAOYSA-N 2-[1-(2-naphthalen-1-ylethyl)imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound C(Cn1cnc(c1)-c1cc(ccn1)C1CNNN1)c1cccc2ccccc12 VCSRTLBBVLAXOM-UHFFFAOYSA-N 0.000 description 1
- IBSRCXFRGADZDI-UHFFFAOYSA-N 2-[1-(2-naphthalen-1-ylethyl)imidazol-4-yl]-4-[5-(trifluoromethyl)triazolidin-4-yl]pyridine Chemical compound FC(F)(F)C1NNNC1c1ccnc(c1)-c1cn(CCc2cccc3ccccc23)cn1 IBSRCXFRGADZDI-UHFFFAOYSA-N 0.000 description 1
- PTYDZYTWDZOYKS-UHFFFAOYSA-N 2-[1-(2-naphthalen-1-ylethyl)imidazol-4-yl]pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC(C=2N=CN(CCC=3C4=CC=CC=C4C=CC=3)C=2)=C1 PTYDZYTWDZOYKS-UHFFFAOYSA-N 0.000 description 1
- LJQBPQLJOCOTBP-UHFFFAOYSA-N 2-[1-(3,4-dihydro-2H-chromen-4-ylmethyl)imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound C(C1CCOc2ccccc12)n1cnc(c1)-c1cc(ccn1)C1CNNN1 LJQBPQLJOCOTBP-UHFFFAOYSA-N 0.000 description 1
- XKMUEGARLKLBEN-UHFFFAOYSA-N 2-[1-[(2,3-dichlorophenyl)methyl]imidazol-4-yl]-4-(5-fluorotriazolidin-4-yl)pyridine Chemical compound FC1NNNC1c1ccnc(c1)-c1cn(Cc2cccc(Cl)c2Cl)cn1 XKMUEGARLKLBEN-UHFFFAOYSA-N 0.000 description 1
- LSSSRKDSCKINJU-UHFFFAOYSA-N 2-[1-[(2,3-dichlorophenyl)methyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound Clc1cccc(Cn2cnc(c2)-c2cc(ccn2)C2CNNN2)c1Cl LSSSRKDSCKINJU-UHFFFAOYSA-N 0.000 description 1
- IKSAXJZJUHKFBB-UHFFFAOYSA-N 2-[1-[(2,3-dichlorophenyl)methyl]imidazol-4-yl]-4-[5-fluoro-1-[(4-methoxyphenyl)methyl]triazol-4-yl]pyridine Chemical compound COC1=CC=C(CN2N=NC(=C2F)C2=CC(=NC=C2)C2=CN(CC3=C(Cl)C(Cl)=CC=C3)C=N2)C=C1 IKSAXJZJUHKFBB-UHFFFAOYSA-N 0.000 description 1
- CXHKXGPWVPZFIK-UHFFFAOYSA-N 2-[1-[(2,3-dichlorophenyl)methyl]imidazol-4-yl]-4-[5-iodo-1-[(4-methoxyphenyl)methyl]triazol-4-yl]pyridine Chemical compound COC1=CC=C(CN2N=NC(=C2I)C2=CC(=NC=C2)C2=CN(CC3=C(Cl)C(Cl)=CC=C3)C=N2)C=C1 CXHKXGPWVPZFIK-UHFFFAOYSA-N 0.000 description 1
- JCGCVOGOLOCZAY-UHFFFAOYSA-N 2-[1-[(2,3-dichlorophenyl)methyl]imidazol-4-yl]pyridine-4-carbonitrile Chemical compound ClC1=CC=CC(CN2C=C(N=C2)C=2N=CC=C(C=2)C#N)=C1Cl JCGCVOGOLOCZAY-UHFFFAOYSA-N 0.000 description 1
- HDHZRVBVYVCGIV-UHFFFAOYSA-N 2-[1-[(2-chlorophenyl)methyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound Clc1ccccc1Cn1cnc(c1)-c1cc(ccn1)C1CNNN1 HDHZRVBVYVCGIV-UHFFFAOYSA-N 0.000 description 1
- UIABJSRPQXKFTQ-UHFFFAOYSA-N 2-[1-[(2-fluoro-3-methoxyphenyl)methyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound COc1cccc(Cn2cnc(c2)-c2cc(ccn2)C2CNNN2)c1F UIABJSRPQXKFTQ-UHFFFAOYSA-N 0.000 description 1
- HPJSIRXBLGEKGD-UHFFFAOYSA-N 2-[1-[(3-chloro-2-fluorophenyl)methyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound Fc1c(Cl)cccc1Cn1cnc(c1)-c1cc(ccn1)C1CNNN1 HPJSIRXBLGEKGD-UHFFFAOYSA-N 0.000 description 1
- SDFJNUZBXZSKBC-UHFFFAOYSA-N 2-[1-[2-(2-chlorophenyl)-2-methylpropyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound CC(C)(Cn1cnc(c1)-c1cc(ccn1)C1CNNN1)c1ccccc1Cl SDFJNUZBXZSKBC-UHFFFAOYSA-N 0.000 description 1
- LXLMEWHQCDXJHZ-UHFFFAOYSA-N 2-[1-[2-(2-chlorophenyl)ethyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound Clc1ccccc1CCn1cnc(c1)-c1cc(ccn1)C1CNNN1 LXLMEWHQCDXJHZ-UHFFFAOYSA-N 0.000 description 1
- BGZOMHLKUBGXRT-UHFFFAOYSA-N 2-[1-[2-(2-chlorophenyl)ethyl]imidazol-4-yl]pyridine-4-carbonitrile Chemical compound ClC1=CC=CC=C1CCN1C=C(C=2N=CC=C(C=2)C#N)N=C1 BGZOMHLKUBGXRT-UHFFFAOYSA-N 0.000 description 1
- VTFFBEJLBGUMQU-UHFFFAOYSA-N 2-[1-[2-(2-chlorophenyl)ethyl]imidazol-4-yl]pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(C=2N=CN(CCC=3C(=CC=CC=3)Cl)C=2)=C1 VTFFBEJLBGUMQU-UHFFFAOYSA-N 0.000 description 1
- VFPFDMMCAORHFL-UHFFFAOYSA-N 2-[1-[2-(2-ethoxyphenyl)ethyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound CCOc1ccccc1CCn1cnc(c1)-c1cc(ccn1)C1CNNN1 VFPFDMMCAORHFL-UHFFFAOYSA-N 0.000 description 1
- PQEKHKZRDSPICQ-UHFFFAOYSA-N 2-[1-[2-(2-ethoxyphenyl)ethyl]imidazol-4-yl]pyridine-4-carbonitrile Chemical compound CCOC1=CC=CC=C1CCN1C=C(C=2N=CC=C(C=2)C#N)N=C1 PQEKHKZRDSPICQ-UHFFFAOYSA-N 0.000 description 1
- ZBLVBMKXUONVTA-UHFFFAOYSA-N 2-[1-[2-(2-ethoxyphenyl)ethyl]imidazol-4-yl]pyridine-4-carboxamide Chemical compound CCOC1=CC=CC=C1CCN1C=C(C=2N=CC=C(C=2)C(N)=O)N=C1 ZBLVBMKXUONVTA-UHFFFAOYSA-N 0.000 description 1
- WWVNYFWLIGCKIA-UHFFFAOYSA-N 2-[1-[2-(2-methoxyphenyl)ethyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound COc1ccccc1CCn1cnc(c1)-c1cc(ccn1)C1CNNN1 WWVNYFWLIGCKIA-UHFFFAOYSA-N 0.000 description 1
- XFIBAXVLOWQHTJ-UHFFFAOYSA-N 2-[1-[2-(2-phenoxyphenyl)ethyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound C(Cn1cnc(c1)-c1cc(ccn1)C1CNNN1)c1ccccc1Oc1ccccc1 XFIBAXVLOWQHTJ-UHFFFAOYSA-N 0.000 description 1
- NJUMTDPBIBAAOL-UHFFFAOYSA-N 2-[1-[2-(2-phenylmethoxyphenyl)ethyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound C(Cn1cnc(c1)-c1cc(ccn1)C1CNNN1)c1ccccc1OCc1ccccc1 NJUMTDPBIBAAOL-UHFFFAOYSA-N 0.000 description 1
- CUINXNYQOPSUKZ-UHFFFAOYSA-N 2-[1-[2-(2-phenylphenyl)ethyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound C(Cn1cnc(c1)-c1cc(ccn1)C1CNNN1)c1ccccc1-c1ccccc1 CUINXNYQOPSUKZ-UHFFFAOYSA-N 0.000 description 1
- XNXSZIGTVRCWQY-UHFFFAOYSA-N 2-[1-[2-[2-(cyclopropylmethoxy)phenyl]ethyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound C(Cn1cnc(c1)-c1cc(ccn1)C1CNNN1)c1ccccc1OCC1CC1 XNXSZIGTVRCWQY-UHFFFAOYSA-N 0.000 description 1
- VKFSWZLZPGCHOR-UHFFFAOYSA-N 2-[1-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound FC(F)(F)c1cccc(Cn2cnc(c2)-c2cc(ccn2)C2CNNN2)c1Cl VKFSWZLZPGCHOR-UHFFFAOYSA-N 0.000 description 1
- AATISDZFMMFUFT-UHFFFAOYSA-N 2-[5-(3-ethoxy-4-fluorophenyl)-1-methylimidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound CCOc1cc(ccc1F)-c1c(ncn1C)-c1cc(ccn1)C1CNNN1 AATISDZFMMFUFT-UHFFFAOYSA-N 0.000 description 1
- YMPZJVJTSJPPIE-UHFFFAOYSA-N 2-[5-(4-fluoro-3-methoxyphenyl)-1-methylimidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound COc1cc(ccc1F)-c1c(ncn1C)-c1cc(ccn1)C1CNNN1 YMPZJVJTSJPPIE-UHFFFAOYSA-N 0.000 description 1
- QSWRYODRTSXOKI-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)-1-methylimidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound Cn1cnc(c1-c1ccc(F)cc1)-c1cc(ccn1)C1CNNN1 QSWRYODRTSXOKI-UHFFFAOYSA-N 0.000 description 1
- GAHZXROHNBVRDK-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)-1-methylimidazol-4-yl]pyridine-4-carbonitrile Chemical compound CN1C=NC(C=2N=CC=C(C=2)C#N)=C1C1=CC=C(F)C=C1 GAHZXROHNBVRDK-UHFFFAOYSA-N 0.000 description 1
- MJUQNYIMIMYHTN-UHFFFAOYSA-N 2-[5-[2-(cyclopropylmethoxy)-4-fluorophenyl]-1-methylimidazol-4-yl]-4-(5-fluorotriazolidin-4-yl)pyridine Chemical compound Cn1cnc(c1-c1ccc(F)cc1OCC1CC1)-c1cc(ccn1)C1NNNC1F MJUQNYIMIMYHTN-UHFFFAOYSA-N 0.000 description 1
- XJCGXRGPKKXJGN-UHFFFAOYSA-N 2-[5-[2-(cyclopropylmethoxy)-4-fluorophenyl]-1-methylimidazol-4-yl]-4-[5-iodo-1-[(4-methoxyphenyl)methyl]triazol-4-yl]pyridine Chemical compound C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)C=1N=NN(C=1I)CC1=CC=C(C=C1)OC XJCGXRGPKKXJGN-UHFFFAOYSA-N 0.000 description 1
- MBIQRVCNAQPEGI-UHFFFAOYSA-N 2-[5-bromo-1-[(2-chlorophenyl)methyl]imidazol-4-yl]-4-(triazolidin-4-yl)pyridine Chemical compound Clc1ccccc1Cn1cnc(c1Br)-c1cc(ccn1)C1CNNN1 MBIQRVCNAQPEGI-UHFFFAOYSA-N 0.000 description 1
- QGUDVVFDWJVNEP-UHFFFAOYSA-N 2-[5-bromo-1-[(2-chlorophenyl)methyl]imidazol-4-yl]pyridine-4-carbonitrile Chemical compound ClC1=CC=CC=C1CN1C(Br)=C(C=2N=CC=C(C=2)C#N)N=C1 QGUDVVFDWJVNEP-UHFFFAOYSA-N 0.000 description 1
- HAWXAHGRJUXDNB-UHFFFAOYSA-N 2-[[6-(1H-imidazol-5-yl)triazolo[4,5-c]pyridin-1-yl]methoxy]ethyl-trimethylsilane Chemical compound C[Si](CCOCN1N=NC=2C=NC(=CC=21)C=1N=CNC=1)(C)C HAWXAHGRJUXDNB-UHFFFAOYSA-N 0.000 description 1
- QQPIMRXROXSIMW-UHFFFAOYSA-N 2-[[6-(5-bromo-1-methylimidazol-4-yl)triazolo[4,5-c]pyridin-1-yl]methoxy]ethyl-trimethylsilane Chemical compound BrC1=C(N=CN1C)C1=CC2=C(C=N1)N=NN2COCC[Si](C)(C)C QQPIMRXROXSIMW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- ZSYMMINAALNVSH-UHFFFAOYSA-N 2h-triazolo[4,5-c]pyridine Chemical compound C1=NC=CC2=NNN=C21 ZSYMMINAALNVSH-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PUVMSKDNBVRDBZ-UHFFFAOYSA-N 4-(5-chlorotriazolidin-4-yl)-2-[1-(2-naphthalen-1-ylethyl)imidazol-4-yl]pyridine Chemical compound ClC1NNNC1c1ccnc(c1)-c1cn(CCc2cccc3ccccc23)cn1 PUVMSKDNBVRDBZ-UHFFFAOYSA-N 0.000 description 1
- QCSFYAUQRHHFFM-UHFFFAOYSA-N 4-(5-iodotriazolidin-4-yl)-2-[1-(2-naphthalen-1-ylethyl)imidazol-4-yl]pyridine Chemical compound IC1NNNC1c1ccnc(c1)-c1cn(CCc2cccc3ccccc23)cn1 QCSFYAUQRHHFFM-UHFFFAOYSA-N 0.000 description 1
- LPVOERDYELZNMX-UHFFFAOYSA-N 4-(triazolidin-4-yl)-2-[1-[2-[2-(2,2,2-trifluoroethoxy)phenyl]ethyl]imidazol-4-yl]pyridine Chemical compound FC(F)(F)COc1ccccc1CCn1cnc(c1)-c1cc(ccn1)C1CNNN1 LPVOERDYELZNMX-UHFFFAOYSA-N 0.000 description 1
- DYROQZRJRBWGMB-UHFFFAOYSA-N 4-(triazolidin-4-yl)-2-[1-[2-[2-(trifluoromethoxy)phenyl]ethyl]imidazol-4-yl]pyridine Chemical compound FC(F)(F)Oc1ccccc1CCn1cnc(c1)-c1cc(ccn1)C1CNNN1 DYROQZRJRBWGMB-UHFFFAOYSA-N 0.000 description 1
- VMIQPRDBLQFIEX-UHFFFAOYSA-N 4-(triazolidin-4-yl)-2-[1-[2-[2-(trifluoromethyl)phenyl]ethyl]imidazol-4-yl]pyridine Chemical compound FC(F)(F)c1ccccc1CCn1cnc(c1)-c1cc(ccn1)C1CNNN1 VMIQPRDBLQFIEX-UHFFFAOYSA-N 0.000 description 1
- BUFFTACKICBKLG-UHFFFAOYSA-N 4-[5-fluoro-1-[(4-methoxyphenyl)methyl]triazol-4-yl]-2-[1-(2-naphthalen-1-ylethyl)imidazol-4-yl]pyridine Chemical compound FC1=C(N=NN1CC1=CC=C(C=C1)OC)C1=CC(=NC=C1)C=1N=CN(C=1)CCC1=CC=CC2=CC=CC=C12 BUFFTACKICBKLG-UHFFFAOYSA-N 0.000 description 1
- RWPISZUNOCYFHY-UHFFFAOYSA-N 4-iodo-2h-triazole Chemical compound IC1=CNN=N1 RWPISZUNOCYFHY-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- GQVDWHUOMWLAPM-UHFFFAOYSA-N 5-[2-[1-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)imidazol-4-yl]pyridin-4-yl]triazolidine-4-carbonitrile Chemical compound N#CC1NNNC1c1ccnc(c1)-c1cn(CC2CCCc3ccccc23)cn1 GQVDWHUOMWLAPM-UHFFFAOYSA-N 0.000 description 1
- CZMNXLFEZKJEEH-UHFFFAOYSA-N 5-[2-[1-(2-naphthalen-1-ylethyl)imidazol-4-yl]pyridin-4-yl]triazolidine-4-carbonitrile Chemical compound N#CC1NNNC1c1ccnc(c1)-c1cn(CCc2cccc3ccccc23)cn1 CZMNXLFEZKJEEH-UHFFFAOYSA-N 0.000 description 1
- RVQMBVGFQUARCY-UHFFFAOYSA-N 5-[2-[1-[(2,3-dichlorophenyl)methyl]imidazol-4-yl]pyridin-4-yl]triazolidine-4-carbonitrile Chemical compound Clc1cccc(Cn2cnc(c2)-c2cc(ccn2)C2NNNC2C#N)c1Cl RVQMBVGFQUARCY-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical compound NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 description 1
- KXJVWNBVRRZEHH-UHFFFAOYSA-N 7,7-dimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2C(=O)C(=O)C1C2(C)C KXJVWNBVRRZEHH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HTVCYNIHVQQEDF-UHFFFAOYSA-N 7H-triazolo[4,5-c]pyridine-6-carboxylic acid Chemical compound N=1N=NC2=CN=C(CC2=1)C(=O)O HTVCYNIHVQQEDF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- HXVYFHLWSBBJSM-UHFFFAOYSA-N C(C1=CC=CC=C1)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound C(C1=CC=CC=C1)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 HXVYFHLWSBBJSM-UHFFFAOYSA-N 0.000 description 1
- QQUIPSDHSZYNRP-UHFFFAOYSA-N C1(=CC=CC2=CC=CC=C12)CCN1C=NC(=C1)C1=NC=CC(=C1)C=O Chemical compound C1(=CC=CC2=CC=CC=C12)CCN1C=NC(=C1)C1=NC=CC(=C1)C=O QQUIPSDHSZYNRP-UHFFFAOYSA-N 0.000 description 1
- IJEOCHNJDZZTLK-UHFFFAOYSA-N C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=CC2=C(C=N1)N=NN2 Chemical compound C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=CC2=C(C=N1)N=NN2 IJEOCHNJDZZTLK-UHFFFAOYSA-N 0.000 description 1
- NCFOJDSSHUALIR-UHFFFAOYSA-N C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)C=1N=NN(C=1F)CC1=CC=C(C=C1)OC Chemical compound C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)C=1N=NN(C=1F)CC1=CC=C(C=C1)OC NCFOJDSSHUALIR-UHFFFAOYSA-N 0.000 description 1
- ITGGNHLGYPVAEF-UHFFFAOYSA-N C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)C=1N=NNC=1C#N Chemical compound C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)C=1N=NNC=1C#N ITGGNHLGYPVAEF-UHFFFAOYSA-N 0.000 description 1
- YRVRJIMUNQZCNL-UHFFFAOYSA-N C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)CO Chemical compound C1(CC1)COC1=C(C=CC(=C1)F)C1=C(N=CN1C)C1=NC=CC(=C1)CO YRVRJIMUNQZCNL-UHFFFAOYSA-N 0.000 description 1
- LGVMSGMOXACFLZ-UHFFFAOYSA-N CC1=CC=CC(CN2C=NC(=C2)C2=NC=CC(=C2)C2=CNN=N2)=C1F Chemical compound CC1=CC=CC(CN2C=NC(=C2)C2=NC=CC(=C2)C2=CNN=N2)=C1F LGVMSGMOXACFLZ-UHFFFAOYSA-N 0.000 description 1
- LPMLMNIJCQIOFM-UHFFFAOYSA-N CCOC1=C(CCN2C=NC(=C2)C2=NC=CC(=C2)C2=C(NN=N2)[Si](C)(C)C)C=CC=C1 Chemical compound CCOC1=C(CCN2C=NC(=C2)C2=NC=CC(=C2)C2=C(NN=N2)[Si](C)(C)C)C=CC=C1 LPMLMNIJCQIOFM-UHFFFAOYSA-N 0.000 description 1
- JMBGPAGLZBKRJX-UHFFFAOYSA-N CN1C=NC(=C1)C1=NC=CC(=C1)C=1N=NNC=1 Chemical compound CN1C=NC(=C1)C1=NC=CC(=C1)C=1N=NNC=1 JMBGPAGLZBKRJX-UHFFFAOYSA-N 0.000 description 1
- ILFZBDXJUZUTOO-UHFFFAOYSA-N COC1=CC=C(CN2N=NC(=C2C(F)(F)F)C2=CC(=NC=C2)C2=CN(CCC3=CC=CC4=CC=CC=C34)C=N2)C=C1 Chemical compound COC1=CC=C(CN2N=NC(=C2C(F)(F)F)C2=CC(=NC=C2)C2=CN(CCC3=CC=CC4=CC=CC=C34)C=N2)C=C1 ILFZBDXJUZUTOO-UHFFFAOYSA-N 0.000 description 1
- WNHKMCWLDXXPDE-UHFFFAOYSA-N C[Si](C)(C)C1=C(N=NN1)C1=CC(=NC=C1)C1=CN(CC2=C(Cl)C=CC=C2)C=N1 Chemical compound C[Si](C)(C)C1=C(N=NN1)C1=CC(=NC=C1)C1=CN(CC2=C(Cl)C=CC=C2)C=N1 WNHKMCWLDXXPDE-UHFFFAOYSA-N 0.000 description 1
- DMQOJZMCGQNZFC-UHFFFAOYSA-N C[Si](C)(C)C1=C(N=NN1)C1=CC(=NC=C1)C1=CN(CCC2=C(Cl)C=CC=C2)C=N1 Chemical compound C[Si](C)(C)C1=C(N=NN1)C1=CC(=NC=C1)C1=CN(CCC2=C(Cl)C=CC=C2)C=N1 DMQOJZMCGQNZFC-UHFFFAOYSA-N 0.000 description 1
- ZBJFCUMFAYMBFP-UHFFFAOYSA-N C[n]1nnc(-c2cc(-c3c[n](CCc4c(cccc5)c5ccc4)cn3)ncc2)c1C(F)(F)F Chemical compound C[n]1nnc(-c2cc(-c3c[n](CCc4c(cccc5)c5ccc4)cn3)ncc2)c1C(F)(F)F ZBJFCUMFAYMBFP-UHFFFAOYSA-N 0.000 description 1
- PVKNJGYTZFHSGT-UHFFFAOYSA-N C[n]1nnc(-c2cc(-c3c[n](CCc4c(cccc5)c5ccc4)cn3)ncc2)c1Cl Chemical compound C[n]1nnc(-c2cc(-c3c[n](CCc4c(cccc5)c5ccc4)cn3)ncc2)c1Cl PVKNJGYTZFHSGT-UHFFFAOYSA-N 0.000 description 1
- 101100322245 Caenorhabditis elegans des-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 238000006964 Chan-Lam coupling reaction Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- NZRMHFYQBPOOHK-UHFFFAOYSA-N ClC1=C(C=CC=C1)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound ClC1=C(C=CC=C1)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 NZRMHFYQBPOOHK-UHFFFAOYSA-N 0.000 description 1
- QWLHZASLSJLTMK-UHFFFAOYSA-N ClC1=C(C=CC=C1)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound ClC1=C(C=CC=C1)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 QWLHZASLSJLTMK-UHFFFAOYSA-N 0.000 description 1
- FQSAHNHNKGGKPW-UHFFFAOYSA-N ClC1=C(N=NN1)C1=CC(=NC=C1)C=1N=CN(C=1C1=C(C=C(C=C1)F)OCC1CC1)C Chemical compound ClC1=C(N=NN1)C1=CC(=NC=C1)C=1N=CN(C=1C1=C(C=C(C=C1)F)OCC1CC1)C FQSAHNHNKGGKPW-UHFFFAOYSA-N 0.000 description 1
- WABUKBFNFSDZAO-UHFFFAOYSA-N ClC1=C(N=NN1CC1=CC=C(C=C1)OC)C1=CC(=NC=C1)C=1N=CN(C=1)CCC1=CC=CC2=CC=CC=C12 Chemical compound ClC1=C(N=NN1CC1=CC=C(C=C1)OC)C1=CC(=NC=C1)C=1N=CN(C=1)CCC1=CC=CC2=CC=CC=C12 WABUKBFNFSDZAO-UHFFFAOYSA-N 0.000 description 1
- APXWBWAYRLIZLQ-UHFFFAOYSA-N ClC1=C(N=NN1CC1=CC=C(C=C1)OC)C1=CC(=NC=C1)C=1N=CN(C=1C1=C(C=C(C=C1)F)OCC1CC1)C Chemical compound ClC1=C(N=NN1CC1=CC=C(C=C1)OC)C1=CC(=NC=C1)C=1N=CN(C=1C1=C(C=C(C=C1)F)OCC1CC1)C APXWBWAYRLIZLQ-UHFFFAOYSA-N 0.000 description 1
- NBFQZZXPJYKQDP-UHFFFAOYSA-N ClC1=CC=C(C=C1)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound ClC1=CC=C(C=C1)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 NBFQZZXPJYKQDP-UHFFFAOYSA-N 0.000 description 1
- RTNFARMIXLCQMZ-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound ClC1=CC=C(C=C1)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 RTNFARMIXLCQMZ-UHFFFAOYSA-N 0.000 description 1
- KJZSHAPRNVEXAD-UHFFFAOYSA-N ClC1=CC=CC(CN2C=NC(=C2)C2=NC=CC(=C2)C2=C(I)NN=N2)=C1Cl Chemical compound ClC1=CC=CC(CN2C=NC(=C2)C2=NC=CC(=C2)C2=C(I)NN=N2)=C1Cl KJZSHAPRNVEXAD-UHFFFAOYSA-N 0.000 description 1
- PXBUOEOSFSTIDA-UHFFFAOYSA-N ClC=1C=C(C=C(C=1)Cl)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound ClC=1C=C(C=C(C=1)Cl)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 PXBUOEOSFSTIDA-UHFFFAOYSA-N 0.000 description 1
- WLHOJGUAXPKUMX-UHFFFAOYSA-N ClC=1C=C(C=CC=1)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound ClC=1C=C(C=CC=1)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 WLHOJGUAXPKUMX-UHFFFAOYSA-N 0.000 description 1
- JBJDLWPSFZCGLI-UHFFFAOYSA-N ClC=1C=C(C=CC=1)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound ClC=1C=C(C=CC=1)N1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 JBJDLWPSFZCGLI-UHFFFAOYSA-N 0.000 description 1
- JHUVNOIUTLYUSM-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 Chemical compound ClC=1C=C(C=CC=1Cl)CN1C=NC(=C1)C1=CC2=C(C=N1)N=NN2 JHUVNOIUTLYUSM-UHFFFAOYSA-N 0.000 description 1
- JJBFXUJAJDMOGR-UHFFFAOYSA-N Clc1ccccc1Cn1cnc(c1)-c1cc(ccn1)C1NNNC1[N+]#[C-] Chemical compound Clc1ccccc1Cn1cnc(c1)-c1cc(ccn1)C1NNNC1[N+]#[C-] JJBFXUJAJDMOGR-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102100024673 Dual specificity protein phosphatase 3 Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VBDCLQQYYCHCRJ-UHFFFAOYSA-N FC(F)(F)C1=C(N=NN1)C1=CC(=NC=C1)C1=CN(CC2=C(Cl)C(Cl)=CC=C2)C=N1 Chemical compound FC(F)(F)C1=C(N=NN1)C1=CC(=NC=C1)C1=CN(CC2=C(Cl)C(Cl)=CC=C2)C=N1 VBDCLQQYYCHCRJ-UHFFFAOYSA-N 0.000 description 1
- NZTCCZUHIHSENS-UHFFFAOYSA-N FC1=C(CN2C=NC(=C2)C2=NC=CC(=C2)C2=CNN=N2)C=CC=C1OC(F)(F)F Chemical compound FC1=C(CN2C=NC(=C2)C2=NC=CC(=C2)C2=CNN=N2)C=CC=C1OC(F)(F)F NZTCCZUHIHSENS-UHFFFAOYSA-N 0.000 description 1
- LTPQCYDCWHATJI-UHFFFAOYSA-N FC1=C(N=NN1)C1=CC(=NC=C1)C=1N=CN(C=1)CCC1=CC=CC2=CC=CC=C12 Chemical compound FC1=C(N=NN1)C1=CC(=NC=C1)C=1N=CN(C=1)CCC1=CC=CC2=CC=CC=C12 LTPQCYDCWHATJI-UHFFFAOYSA-N 0.000 description 1
- DFIZSWCEVFIDEP-UHFFFAOYSA-N FC1=CC=C(C=C1)C1=C(N=CN1C)C1=CC2=C(C=N1)N=NN2 Chemical compound FC1=CC=C(C=C1)C1=C(N=CN1C)C1=CC2=C(C=N1)N=NN2 DFIZSWCEVFIDEP-UHFFFAOYSA-N 0.000 description 1
- JDMPNXRNODQMST-UHFFFAOYSA-N FC1=CC=C(C=C1)C1=C(N=CN1C)C1=NC=CC(=C1)C=1N=NNC=1[Si](C)(C)C Chemical compound FC1=CC=C(C=C1)C1=C(N=CN1C)C1=NC=CC(=C1)C=1N=NNC=1[Si](C)(C)C JDMPNXRNODQMST-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 101000908482 Homo sapiens Dual specificity protein phosphatase 3 Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101000613625 Homo sapiens Lysine-specific demethylase 4A Proteins 0.000 description 1
- 101000692954 Homo sapiens Lysine-specific demethylase PHF2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100040863 Lysine-specific demethylase 4A Human genes 0.000 description 1
- 102100026395 Lysine-specific demethylase PHF2 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- IMUKZGZNBVRXBT-UHFFFAOYSA-N N1N=NC=2C=NC(=CC21)C=O Chemical compound N1N=NC=2C=NC(=CC21)C=O IMUKZGZNBVRXBT-UHFFFAOYSA-N 0.000 description 1
- JSGDESHALYEAHD-UHFFFAOYSA-N N1N=NC=2C=NC(=CC=21)C=1N=CN(C=1)CC(F)(F)F Chemical compound N1N=NC=2C=NC(=CC=21)C=1N=CN(C=1)CC(F)(F)F JSGDESHALYEAHD-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930183415 Suberin Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- OOUXSBQUOQDRRU-UHFFFAOYSA-N [1-(2-trimethylsilylethoxymethyl)triazolo[4,5-c]pyridin-6-yl]methanol Chemical compound C[Si](CCOCN1N=NC=2C=NC(=CC=21)CO)(C)C OOUXSBQUOQDRRU-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000005875 benzo[b][1,4]dioxepinyl group Chemical group 0.000 description 1
- 125000005876 benzo[b][1,4]oxazinyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- WIKQEUJFZPCFNJ-UHFFFAOYSA-N carbonic acid;silver Chemical compound [Ag].[Ag].OC(O)=O WIKQEUJFZPCFNJ-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical group C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000001890 gluconeogenic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 102000033785 histone binding proteins Human genes 0.000 description 1
- 108091009732 histone binding proteins Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- KRCRBPOPADYUHO-UHFFFAOYSA-N methyl 1-(2-trimethylsilylethoxymethyl)triazolo[4,5-c]pyridine-6-carboxylate Chemical compound C[Si](CCOCN1N=NC=2C=NC(=CC=21)C(=O)OC)(C)C KRCRBPOPADYUHO-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- NOUUUQMKVOUUNR-UHFFFAOYSA-N n,n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1NCCNC1=CC=CC=C1 NOUUUQMKVOUUNR-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000032393 negative regulation of gluconeogenesis Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Chemical group C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- DEDZSLCZHWTGOR-UHFFFAOYSA-N propylcyclohexane Chemical compound CCCC1CCCCC1 DEDZSLCZHWTGOR-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- KQTXIZHBFFWWFW-UHFFFAOYSA-L silver(I) carbonate Inorganic materials [Ag]OC(=O)O[Ag] KQTXIZHBFFWWFW-UHFFFAOYSA-L 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- WGZVQAZCALOGIM-UHFFFAOYSA-N tributyl-(1-tritylimidazol-4-yl)stannane Chemical compound C1=NC([Sn](CCCC)(CCCC)CCCC)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WGZVQAZCALOGIM-UHFFFAOYSA-N 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051268P | 2014-09-16 | 2014-09-16 | |
| US62/051,268 | 2014-09-16 | ||
| PCT/US2015/050289 WO2016044342A1 (en) | 2014-09-16 | 2015-09-15 | Histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527590A JP2017527590A (ja) | 2017-09-21 |
| JP2017527590A5 JP2017527590A5 (https=) | 2018-10-25 |
| JP6660060B2 true JP6660060B2 (ja) | 2020-03-04 |
Family
ID=55533770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514411A Expired - Fee Related JP6660060B2 (ja) | 2014-09-16 | 2015-09-15 | ヒストンデメチラーゼ阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9676770B2 (https=) |
| EP (1) | EP3193881B1 (https=) |
| JP (1) | JP6660060B2 (https=) |
| KR (1) | KR20170048590A (https=) |
| CN (1) | CN107073006A (https=) |
| AU (1) | AU2015317904A1 (https=) |
| BR (1) | BR112017005128A2 (https=) |
| CA (1) | CA2961525A1 (https=) |
| CL (1) | CL2017000643A1 (https=) |
| CO (1) | CO2017002772A2 (https=) |
| EA (1) | EA201790502A1 (https=) |
| EC (1) | ECSP17020172A (https=) |
| ES (1) | ES2911292T3 (https=) |
| IL (1) | IL251103A0 (https=) |
| MX (1) | MX2017003464A (https=) |
| SG (1) | SG11201702108PA (https=) |
| WO (1) | WO2016044342A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019508447A (ja) * | 2016-03-15 | 2019-03-28 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2731773T3 (es) | 2013-03-14 | 2019-11-19 | Celgene Quanticel Res Inc | Inhibidores de la histona desmetilasa |
| US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| BR112017005128A2 (pt) * | 2014-09-16 | 2018-07-31 | Celgene Quanticel Res Inc | inibidores de histona desmetilase |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| WO2017120194A1 (en) * | 2016-01-05 | 2017-07-13 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| KR20240152947A (ko) | 2017-10-18 | 2024-10-22 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN111116571B (zh) * | 2019-12-27 | 2022-07-12 | 吉首大学 | 含恶唑及三唑双杂环的化合物及其制备与应用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000038683A1 (en) | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
| CA2427284A1 (en) | 2000-10-26 | 2002-05-30 | Tularik Inc. | Antiinflammation agents |
| GB0217780D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| US20040127733A1 (en) | 2002-10-31 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions |
| DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| CA2632444A1 (en) | 2005-12-19 | 2007-06-28 | Boehringer Ingelheim International Gmbh | Use of aminoalcohol derivatives for the treatment of overactive bladder |
| MX2010003563A (es) | 2007-10-03 | 2010-06-02 | Vertex Pharma | Inhibidores de proteina cinasa de c-met. |
| DE102009019962A1 (de) | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate |
| WO2011058474A1 (en) | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CN103221047B (zh) | 2010-01-13 | 2014-12-17 | 坦颇罗制药股份有限公司 | 化合物和方法 |
| EP2928471B1 (en) * | 2012-12-06 | 2020-10-14 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| ES2731773T3 (es) * | 2013-03-14 | 2019-11-19 | Celgene Quanticel Res Inc | Inhibidores de la histona desmetilasa |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9896436B2 (en) * | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| BR112017005128A2 (pt) | 2014-09-16 | 2018-07-31 | Celgene Quanticel Res Inc | inibidores de histona desmetilase |
-
2015
- 2015-09-15 BR BR112017005128A patent/BR112017005128A2/pt not_active Application Discontinuation
- 2015-09-15 AU AU2015317904A patent/AU2015317904A1/en not_active Abandoned
- 2015-09-15 WO PCT/US2015/050289 patent/WO2016044342A1/en not_active Ceased
- 2015-09-15 SG SG11201702108PA patent/SG11201702108PA/en unknown
- 2015-09-15 KR KR1020177009901A patent/KR20170048590A/ko not_active Withdrawn
- 2015-09-15 EA EA201790502A patent/EA201790502A1/ru unknown
- 2015-09-15 CA CA2961525A patent/CA2961525A1/en not_active Abandoned
- 2015-09-15 MX MX2017003464A patent/MX2017003464A/es unknown
- 2015-09-15 JP JP2017514411A patent/JP6660060B2/ja not_active Expired - Fee Related
- 2015-09-15 CN CN201580060763.8A patent/CN107073006A/zh active Pending
- 2015-09-15 ES ES15842092T patent/ES2911292T3/es active Active
- 2015-09-15 US US14/855,269 patent/US9676770B2/en active Active
- 2015-09-15 EP EP15842092.7A patent/EP3193881B1/en not_active Not-in-force
-
2017
- 2017-03-12 IL IL251103A patent/IL251103A0/en unknown
- 2017-03-16 CL CL2017000643A patent/CL2017000643A1/es unknown
- 2017-03-23 CO CONC2017/0002772A patent/CO2017002772A2/es unknown
- 2017-03-31 EC ECIEPI201720172A patent/ECSP17020172A/es unknown
- 2017-05-05 US US15/588,495 patent/US10071984B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019508447A (ja) * | 2016-03-15 | 2019-03-28 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3193881B1 (en) | 2022-02-09 |
| US20160108033A1 (en) | 2016-04-21 |
| US10071984B2 (en) | 2018-09-11 |
| MX2017003464A (es) | 2017-07-13 |
| US9676770B2 (en) | 2017-06-13 |
| CO2017002772A2 (es) | 2017-06-09 |
| CA2961525A1 (en) | 2016-03-24 |
| US20170240529A1 (en) | 2017-08-24 |
| SG11201702108PA (en) | 2017-04-27 |
| ECSP17020172A (es) | 2017-05-31 |
| IL251103A0 (en) | 2017-04-30 |
| EP3193881A1 (en) | 2017-07-26 |
| EP3193881A4 (en) | 2018-02-21 |
| BR112017005128A2 (pt) | 2018-07-31 |
| CN107073006A (zh) | 2017-08-18 |
| KR20170048590A (ko) | 2017-05-08 |
| CL2017000643A1 (es) | 2017-12-01 |
| WO2016044342A1 (en) | 2016-03-24 |
| EA201790502A1 (ru) | 2017-10-31 |
| JP2017527590A (ja) | 2017-09-21 |
| AU2015317904A1 (en) | 2017-04-06 |
| ES2911292T3 (es) | 2022-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6660060B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6273621B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6276378B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| CN106659914B (zh) | 赖氨酸特异性脱甲基酶-1的抑制剂 | |
| JP6256771B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6970680B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP2020169183A (ja) | ヒストンデメチラーゼ阻害剤 | |
| US10174003B2 (en) | Histone demethylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180913 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180914 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190529 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190806 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191127 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191223 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6660060 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |